本帖最后由 老马 于 2013-3-13 13:43 编辑
% o6 h- N% h# K2 C0 a @7 y: r6 v
健择（吉西他滨）+顺铂+阿瓦斯汀+ D5 e" _/ n1 y
Gemzar +Cisplatin + Avastin
+ x7 x8 B6 ^7 T3 T% E7 w; R! Nhttp://annonc.oxfordjournals.org/content/21/9/1804.full
* j( K8 |: l# L% D, y- x5 JOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 4 C$ V3 R" i2 B' [
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
# Z" J) w) y# }$ uResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 6 x% E& Y3 S2 ]9 m0 `) i: L
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1141)
! f: O# [0 K& k2 e2 ]7 L4 e: s华为网盘附件：
0 x5 y3 `/ @$ V4 \. m5 B% }% g【华为网盘】ava.JPG: d. @; }" C" a5 M( @% ^1 t
|
11011102001537 )
显身卡
